Skip to main content
. 2011 Jul;80(1):60–67. doi: 10.1124/mol.110.070458

Fig. 2.

Fig. 2.

Functional expressions of both DGL-α and DGL-β are required for RA induced differentiation of Neuro-2a cells. Neuro-2a cells were incubated with 20 μM RA for the indicated times, and DGL-α (A) or DGL-β (B) mRNA levels were measured by quantitative real-time PCR. mRNA levels for CB1 receptor (CB1R), MGL, ABHD6, and an internal control 18S were quantified after 3 days of RA treatment (n = 4) (C). D, Neuro-2a cells were transfected with the following shRNA-expressing constructs; the nontargeting control (LacZi), DGL-α-targeting (DGL-αi), DGL-β-targeting (DGL-βi), or both DGL-α-targeting and DGL-β-targeting (DGL-αi + DGL-βi). After 24 h, cells were treated with 20 μM RA for 40 h at 37°C (n = 6). E, neuritogenic effects of 2-AG ether (Noladin ether, 10 μM), an MGL inhibitor JZL184 (JZL, 1 μM), and an ABHD6 inhibitor WWL70 (WWL, 10 μM) were determined upon 48 h of treatments (n = 6). *, P < 0.05, **, P < 0.01, ***, P < 0.001 by two-tailed t test.